Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Estrogens, esterified (USP) / methyltestosterone price, strengths & recalls

Estrogens, esterified (USP) / methyltestosterone has no weekly pharmacy acquisition cost. 2 manufacturers make it. Its official label last changed on April 24, 2026.

Generic
No weekly pricePharmacy acquisition costs aren't published for this drug - usually because it's given in clinics or hospitals.

Estrogens, esterified (USP) / methyltestosterone price by strength

What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
0.625 mg / 1.25 mg tabletNot priced this week
1.25 mg / 2.5 mg tabletNot priced this week

Supply status: shortages & recalls

No shortage reportedChecked Nov 17, 2026
No ongoing recallsNone on record

What did you pay for estrogens, esterified (usp) / methyltestosterone? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedApril 24, 2026
Version103 of 4
EffectiveApr 22, 2026
Read the label

Esterified Estrogens and Methyltestosterone TabletsRx Only

This drug has a boxed warning

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER

Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of "natural" estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (See WARNINGS, Malignant Neoplasms, Endometrial Cancer.)

CARDIOVASCULAR AND OTHER RISKS

Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (See WARNINGS, Cardiovascular Disorders.)

The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See CLINICAL PHARMACOLOGY, Clinical Studies.)

The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.)

Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
None on the market

Estrogens, esterified (USP) / methyltestosterone questions

Is estrogens, esterified (usp) / methyltestosterone in shortage?

No shortage is reported for estrogens, esterified (usp) / methyltestosterone right now. We check the national shortage list every day.

Has estrogens, esterified (usp) / methyltestosterone been recalled?

No recalls are on record for estrogens, esterified (usp) / methyltestosterone.

When did the estrogens, esterified (usp) / methyltestosterone label last change?

The official label was last updated on April 24, 2026 (version 103). See what changed.

Talk about estrogens, esterified (usp) / methyltestosterone

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.